Baird Raises Intuitive Surgical (ISRG) Price Target to $550
Key Points
- Baird maintained an Outperform rating on Intuitive Surgical, Inc. on October 21, 2026, while raising its price target to $550 from $513.
- Baird's $550 price target implies 25.57% upside from Intuitive Surgical, Inc.'s ($ISRG) current $438.02 share price.
- The stock recently traded near $438.02, sitting below Baird's new target and roughly 20.4% under the broader analyst consensus target.
- Intuitive Surgical reported trailing twelve-month revenue of $11.03 billion alongside an EPS of $8.85.
Get Intuitive Surgical text alerts
We text you when insiders, Congress, analysts or big funds move on $ISRG.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Intuitive Surgical, Inc. alert may contain errors. Disclosures
On October 21, 2026, Baird maintained its Outperform rating on Intuitive Surgical, Inc. (NasdaqGS: ISRG) and raised its price target from $513 to $550. According to the research note, the firm kept its positive stance on the medical device maker while increasing its expected value for the shares.
ISRG
Intuitive Surgical, Inc.
Baird vs. the S&P 500
Hypothetical returns from Baird's disclosed trades, not real profit or advice. How we model this.
Baird's Call on Intuitive Surgical
Baird issued its updated research note on October 21, 2026, keeping an Outperform rating while lifting the target by $37. The firm's new $550 price target suggests room for growth from where the shares recently traded.
Other Institutional Activity in Intuitive Surgical
Other large funds have been adjusting their holdings in the medical device maker. Davenport trimmed its position by 145,132 shares, ending the period with 8,095 shares valued at about $3.29 million.
Intuitive Surgical, Inc. Stock Up 2.7%
Intuitive Surgical recently traded around $438.02 on October 21, 2026, closing at $438.00 on the prior trading day of October 20, 2026. The shares sit about 11.5% above their 50-day moving average of $392.76 and roughly 0.2% below their 200-day moving average of $438.97. The stock trades 27.5% below its 52-week high of $603.88 and 33.3% above its 52-week low of $328.57. With a mean analyst target price of $478.53 across 30 opinions, the stock trades about 8.5% below that average consensus level.
$ISRG price target
Intuitive Surgical, Inc. daily closes and this analyst's $550 target. Not advice.
Recent Earnings
Intuitive Surgical reported trailing twelve-month revenue of $11.04 billion and an EPS of $8.85. The company maintains a net profit margin of 28.4% and a return on equity of 17.4%.
Dividend
Intuitive Surgical currently pays no dividend, registering a dividend payout ratio and yield of 0.0%.
Insider Buying and Selling at Intuitive Surgical, Inc.
Company insiders executed several stock sales prior to the analyst update. Officer Mark Preston Brosius sold 154 shares for $59,439 on August 21, 2026, followed by a sale of 69 shares worth $24,671 on September 9, 2026, and 48 shares worth $17,141 on September 11, 2026. Later, officer Fredrik Widman sold 1,089 shares at $374.44 each for a total of $407,765 on September 15, 2026.
Analysts Set New Price Targets
Wall Street firms have actively adjusted their views on the company. BTIG kept a Buy rating with a $469 target on September 8, 2026, and Barclays initiated coverage with an Overweight rating and a $485 target on October 7, 2026. BTIG maintained its Buy rating on October 12, 2026, adjusting its target to $454, and later reiterated that same $454 target on October 21, 2026. Across the broader analyst community, the stock carries a consensus buy rating from 30 analysts.
About Intuitive Surgical
Intuitive Surgical, Inc. develops, manufactures, and markets robotic-assisted systems that help physicians perform minimally invasive surgeries. Headquartered in Sunnyvale, California, the company provides advanced surgical technology to hospitals and healthcare providers around the world.
Bottom Line
Investors will continue to monitor how Intuitive Surgical trades relative to Baird's new $550 price target. Watch for future analyst updates and upcoming earnings reports to gauge market demand for the company's surgical platforms.
Related Filing Alerts
Source: Baird's rating change on $ISRG (Oct 21, 2026). Written by software, not financial advice. How we make alerts